Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tergase injection for scar changes after excision of benign skin tumors
KCT0012784Phase 4Not yet recruiting
- Sponsor
- Alteogen
- Start
- Oct 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of tergase in severe cutaneous adverse reactions (SCAR), Hypertrophic Scar (HS), sponsored by Alteogen. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tergase
03
Conditions
severe cutaneous adverse reactions (SCAR)Hypertrophic Scar (HS)
Beyond the preview
Go deeper on KCT0012784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012784.